Sanger Institute

Milner Therapeutics Institute, Pfizer partner

Friday, January 20, 2017

The Milner Therapeutics Institute has announced Pfizer as a partner to the Milner Therapeutics Consortium. Pfizer has agreed to join the Consortium, which enables the efficient transfer of materials between industry and academia and allocation of funds for partnering opportunities in Cambridge. Dr. Ron Newbold, vice president, External R&D Innovation at Pfizer, will join the Milner Innovation Board alongside representatives from Astex, AstraZeneca, GlaxoSmithKline, Shionogi, MedImmune, University of Cambridge, Babraham Institute and Sanger Institute.

[Read More]

Biodata innovation centre and new sequencing facility launched in the U.K.

Tuesday, November 29, 2016

The U.K. Prime Minister Rt Hon Theresa May has joined key stakeholders from across the life sciences sector to open the Wellcome Trust Sanger Institute’s new Bridget Ogilvie Building and the Biodata Innovation Centre at the Wellcome Genome Campus in Cambridge.

The Sanger Institute is one of the world’s leading genome centers and a major U.K. scientific success story. Together these new buildings will house one of the world’s most advanced gene sequencing facilities and a unique innovation space for global genomics and biodata businesses. These buildings will be home to a powerful collaboration between academia, businesses large and small, charities and Government.

The Ogilvie Building houses the Sanger Institute’s genome sequencing facility which has expertise in sequencing genomes from humans, pathogens and many other species with samples arriving from all corners of the world. It also houses the Genomics England sequencing operation which is delivering the 100,000 Genomes Project. The project will enable the NHS to become the first mainstream health service in the world to offer genomic medicine as part of routine care.

“The UK is recognized across the world for being the first nation to introduce whole-genome sequencing at scale in routine care environments. The Ogilvie facility is central to that achievement and opens the way to the virtuous circle of treating patients with genomic medicine leading to knowledge creation leading to advanced therapies leading to superior health outcomes.”

Sir John Chisholm, executive chairman of Genomics England, said, “The Biodata Innovation Centre houses start-up companies in the field of genomics emanating from local academic research, as well as cutting edge companies attracted from around the world—already businesses have moved to the Centre from the U.S., Europe and Asia—to collaborate with the UK’s best scientists.

“Genomes and biodata are an important part of all our futures. The Campus is home to research institutes, spin-out and start-up companies, academic-industry partnerships and Genomics England; all dedicated to driving and leading pioneering research and innovation and discourse in the sphere of genomes and biodata.

“The new buildings mark the next major step in the progression of our vision for this Campus as a global hub for genomics and biodata. We have an ambition to translate and commercialize research findings, as well as inform and enable the NHS to integrate genomics into clinical care.”

Professor Sir Mike Stratton, director of the Wellcome Trust Sanger Institute and chief executive of the Wellcome Genome Campus, said, “Genome sequencing is already changing the face of medicine, making possible more accurate and personalized treatments than ever before. Wellcome is delighted to build on its support of over 20 years standing with the launch of the Sanger Institute’s new sequencing and business incubation centers, which will accelerate further the application of genomics to human health and create significant economic benefits for the U.K.”

Dr Jeremy Farrar, Wellcome’s director, said, “It is an honor to open these buildings as they truly represent cutting edge British science and business in the modern era. What I’ve seen on the Wellcome Genome Campus is an excellent example of research from across the U.K. and around the world coming together with commerce to deliver benefits for everybody including patients in the NHS. We want the U.K. to be the ‘go to’ place for scientists, innovators, businesses and investors. This really is a very good example of that.”